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The aim of this study was to evaluate symptom persistence in attention-deficit/
hyperactivity disorder (ADHD), the development of comorbidities, and psychostimulant
usage patterns. Follow-up studies were conducted in 37 patients with ADHD and 22
healthy controls, aged 10 and 18, 4 years after their first assessment. The ADHD was
rated as persistent if participants met all DSM-IV criteria for syndromic or sub-threshold
persistence, or had functional impairments (functional persistence). Of the 37 ADHD
patients we reevaluated, 75% had persistent symptoms, and psychiatric comorbidities
with additional functional impairments and academic problems were more common than
in controls. These follow-up findings show a high comorbidity associated with ADHD
and support the importance of evaluation and treatment for ADHD and comorbidities
throughout life.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a childhood-onset neurodevelopmental condi-
tion characterized by age-inappropriate levels of inattention, hyperactivity, and impulsivity (1), and
it is the most common of the neurodevelopmental disorders (2). It is multifactorial and clinically
heterogeneous (3), with a worldwide prevalence rate of 5.3% (4) and a prevalence rate of 5–10% in
school-aged children (5, 6).
Although ADHD is a neurodevelopmental disorder, hyperactivity–impulsivity symptoms
declined with increasing age, but inattention symptoms did not (7–9), and many patients maintain
symptoms into adolescence (75%) and adulthood (66%) (10–12).
Moreover, ADHD is frequently associated with psychiatric comorbidities, such as anxiety dis-
orders (30–40%), (13, 14), and conduct disorder (CD)/oppositional defiance disorder (ODD)
(30–50%), (10). Psychiatric comorbidities might influence the clinical presentation of ADHD and
may hinder the differential diagnosis of disorders. Diagnoses of ADHD can be easily confused
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if symptoms of impulsivity are decreased with anxiety or if symp-
toms of inattention are seen as secondary to comorbid psychiatric
conditions (15).
Thus, the persistence of ADHD symptoms is a risk factor for
a number of adverse outcomes in adolescence and adulthood,
especially when there are comorbidities. It is associated with con-
tinuing social, educational, occupational, interpersonal difficul-
ties, substance use disorders, driving difficulties and accidents,
and delinquency problems (1, 8, 16–18). Thus, the associations
between the high prevalence, the persistence of symptoms, and
the presence of comorbidities make the study of ADHD very
interesting, important, and challenging.
There have been several follow-up studies of children docu-
menting the persistence of ADHD into adolescence and adult-
hood (7, 12, 19–34). However, almost all of these studies were con-
ducted in clinical samples in North America. Culture can affect
different aspects of development, such as language development,
behavioral expectations, parental tolerance for non-compliant
behaviors, emotional regulation, binding styles, identity forma-
tion, motivation, and other aspects of parenting and early child-
hood education (35). Therefore, the diagnosis of ADHD and its
evolution may be affected by cultural factors. Thus, it is difficult
to generalize these results to other countries. In Brazil, there is a
lack of follow-up of patients withADHDdiagnoses. A brief survey
of the literature found only two follow-up studies in our country,
by the same group of researchers (25, 36).
Thus, a prospective longitudinal follow-up study was designed
to (a) investigate ADHD symptom persistence and full remission
over these 4 years and to (b) track comorbidities and psychostim-
ulant use.
Materials and Methods
The project was approved by the Research Ethics Committee of
UNIFESP-HSP (protocol # 1616/06). All patients, healthy con-
trols, and their families were informed of the procedures involved.
Thosewho agreed to participate signed an informed consent form.
Baseline
The baseline sample was selected from January 2007 to Decem-
ber 2007. This sample included children and adolescents with
ADHD, visiting the Interdisciplinary Neuropsychological Child
Care Center (NANI), Department of Psychobiology, UNIFESP.
NANI is an outpatient facility specialized in interdisciplinary
research on diagnosing neurodevelopmental disorders, delivering
care, researching and teaching, specialized in ADHD. The sample
at baseline consisted of 38 patients (31 boys, 7 girls), diagnosed
with ADHD at a mean age of 8.7 years (SD= 2.3). The healthy
subjects were matched to the ADHD patients for gender, age, level
of education, and type of school attended (i.e., public or private).
Their mean age was 8.8 years (SD= 1.8).
The inclusion criteria were as follows: (1) a full diagnosis of
ADHD according to DSM-IV, (2) no comorbid mental disorders,
(3) no history of psychostimulant medication use or any other
medication that might interfere with cortisol secretion, (4) no
history of a serious medical illness, and (5) an IQ score higher
than 75 points. These strict criteria were responsible for the small
number of participants.
Follow-Up
At follow-up, 4 years later, 37 patients (30 boys and 7 girls) and
22 healthy subjects (15 boys and 7 girls) were included. Their
ages ranged from 10 to 18. They were contacted by mail, e-mail,
telephone, or through their school. In the ADHD group, there was
a loss of one patient for failure to locate. The control group lost 16
children and adolescents, 8 for failure to locate and 8 because the
family refused to participate in the research.
Diagnostic Evaluation
Baseline
The diagnosis of ADHD was based on the application of a Brazil-
ian version of the SNAP-IV (Swanson, Nolan e Pelham – version
IV) and the Child Behavior Checklist (CBCL). The SNAP-IV
is a questionnaire consisting of symptoms from the Diagnostic
and Statistical Manual – Fourth Edition – DSM-IV (37) that has
already been validated in Brazil (38). The CBCL is a questionnaire
that assesses social competence and behavioral problems from
ages 4 to 18 years, from information provided by the parents,
previously validated in Brazil (39). Both were answered by par-
ents or guardians. A social evaluation was conducted with the
Brazil Criteria of Economic Classification, a self-reported ques-
tionnaire – the ABEP (40). All assessments were conducted by two
board-certified medical doctors (one psychiatrist and one pedi-
atric neurologist) with many years of experience (over 25 years)
in clinical evaluation and research. The children underwent a
battery of neuropsychological tests. At the end of this evaluation,
their cases were discussed by the service team and the diagnoses
established.
Follow-Up
Behavioral and comorbidity symptoms were reassessed using
the CBCL questionnaire. The CBCL has been widely used for
screening comorbidity disorders in samples of patients with
ADHD (41–43).
Symptom persistence was defined based on the concepts pro-
posed by Biederman et al. (17, 29): (a) subjects meeting full DSM-
IV criteria for ADHD (“Syndromic Persistence”); (b) subjects
meeting sub-threshold DSM-IV criteria [more than half of the
symptoms required for a full diagnosis (“Symptomatic Persis-
tence”)]; (c) subjects not meeting criteria (a) or (b) but function-
ally impaired as assessed by the global assessment of functioning
(GAF) (37) and displaying a score60 (“Functional Persistence”)
in the month prior to the subject’s 4-year follow-up assessment.
The social reevaluation used the ABEP.
Statistical Analysis
Statistical Package for the Social Sciences (SPSS) version 20.0
was used for all statistical analyses. The data were analyzed
using descriptive statistical procedures for analyzing and testing
hypotheses according to the nature of the variables (quantitative
or qualitative) and the sample type (independent or paired). The
normality analysis in the samples distribution was performed
using Kolmorov–Smirnov test. For samples with normal distribu-
tion, parametric tests were adopted. The analysis of quantitative
variables, involving the comparison of independent samples, used
one-way ANOVA and Student’s t-tests. The analysis of qualitative
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variables in independent samples used the chi-squared test. For
data collected longitudinally (including the number of symp-
toms from the DSM-IV), involving paired samples, the Split-Plot
ANOVA for repeated measures, and Student’s t-test for paired
samples were used. For all tests, a significance level of 5% was
established.
Results
Demographic Results
Thirty-seven out of the 38 previous ADHD-diagnosed patients
were evaluated in the follow-up study. The mean age of the
adolescents was 13.1 (SD= 2.5) for the remittent ones and 12.4
(SD= 2.1) for the persistent patients in the ADHD group, and
12 (SD= 1.9) in the clinical control group. There were no signif-
icant age differences between the two groups (p= 0.86). Thirty-
one (83.8%) boys and 7 (16.2%) girls were in the ADHD group,
whereas 15 (68.2%) boys and 7 (31.8%) girls were in the clin-
ical control group. Male to female ratio in the ADHD group
was 4/1. The loss of the healthy subjects was due to an inabil-
ity to located them (N= 8) or to family members’ refusal to
participate (N = 8).
Of the 37 patients, 22 (59%) had experienced suspension and/or
expulsion during the previous school year. In the ADHD group,
only seven were treated with methylphenidate. Almost half of
our sample, 47% (N = 14) had at least one grade-level repetition
during their school progression and 22 patients had received
warnings of possible problems/suspensions/expulsions school, in
the previous year before the follow-up. One was arrested and was
in a prison for teenagers for stealing and the use of psychoactive
substances for the third time at the time of data collection.
Persistence of Symptoms
Twenty-eight out the 37 ADHD patients at follow-up showed
symptom persistence (75%) and 9 (25%) showed full remis-
sion. Symptom persistence was as follows: 13 (46.4%) ful-
filled all diagnostic criteria (syndromic persistence), 10 (35.7%)
fulfilled sub-threshold criteria symptoms (symptomatic persis-
tence), and 5 (17.8%) had functional impairments (functional
persistence).
The descriptive data of the participants and the characteris-
tics of the ADHD group regarding the persistence or absence of
symptoms are shown in Table 1.
Frequencies of Comorbidities
In the sample, 33.1% (13/37) had none of the investigated comor-
bidities, 13.5% (5) had at least one comorbid disorder, and 51.3%
(19) had 2 or more disorders. In the persistent ADHD group, only
18% (5/28) did not have comorbidities.
Associations Among Comorbid Disorders and
Persistence of Symptoms
Persistent ADHD was significantly associated with significant
rates of ODD 70% (n= 19), CD 70% (n= 19), and affective prob-
lems, such as dysthymia (DD) and major depressive episodes
(MDD) 74% (n= 20) compared with controls. Remitted patients
did not differ from controls (see Table 2).
TABLE 1 |Demographic and clinical characteristics of the control and ADHD
groups, expressed as meansSD or percentage (%).
Control ADHD ANOVA or
chi-square
p-Values
Remittent Persistent
(N=22) (N=9) (N=28)
IQ 122.5 (17.7) 83.2 (50.8) 90.8 (28.7) F (3, 59)= 2.26 0.45
Age (years) 12 (1.9) 13.1 (2.5) 12.4 (2.1)a,* F (3, 59)= 1.44 0.01**
ABEP 19.7 (1.9) 19.3 (3.6) 15.9 (4.6)b,* F (3, 59)= 0.19 0.001*
School N (%) N (%) N (%) χ2(2)=0.47 0.01**
Particular 12 (54) 1 (14) 18 (64)
Public 10 (46) 6 (86) 9 (36)
Medication N (%) N (%) N (%) χ2(1)=0.47 0.49
Use – 1 (88) 6 (78)
No – 8 (12) 22 (22)
IQ, intellectual quotient; ABEP, socioeconomic classification; GAF, global assessment of
functioning.
Data were analyzed by ANOVA and chi-square test.
*p0.001; **p 0.01; aPersistent vs. Controls; bPersistent vs. Remittent.
TABLE 2 | Prevalence of comorbidity at follow-up between control and
ADHD groups.
Persistent
(N=27)
Remittent
(N=9)
Controls
(N=19)
Test
statistic
p-Values
N (%) N (%) N (%)
Affective 20 (74)a**,b** 0 (0) 4 (21) χ2(2)= 21.07 <0.001
Anxiety 15 (55) 3 (33) 7 (37) χ2(2)= 2.21 0.33
Somatic 8 (30) 5 (55) 3 (16) χ2(2)= 4.68 0.09
Attentional 23 (85)a**,b** 3 (33) 2 (10) Fischer’s <0.001
Oppositional 19 (70)a*,b** 1 (11) 5 (26) χ2(2)= 13.25 0.001
Conduct 19 (70)a**,b** 0 (0) 1 (5) χ2(2)= 0.47 <0.001
a=vs. Controls; b=vs. Remittent.
Data were analyzed by chi-square test and Fisher’s exact test.
*p0.05; **p 0.01.
Discussion
In this 4-year follow-up, symptomatic persistence was associated
with high rates of comorbidities, a low number of patients in
treatment for ADHD and school problems.
In the past, it was believed that ADHD symptoms persisted
until mild-adolescence, but now there are signs of their often
continuing throughout adolescence and into early adulthood (44).
Corroborating these findings, our results showed that three quar-
ters of the current sample presented with some type of ADHD
symptom persistence 4 years after the first evaluation, and almost
half met syndromic persistence criteria. This rate of persistence
differs slightly from other follow-up studies. Biederman et al. (30)
reported a 35% persistence rate for full ADHD diagnosis and 22%
when partial remission cases were included, and Mick et al., (8)
found 71% persistence rates. Persistence rates found in this study
may reflect the difficulty in recognizing mental health problems
in children and adolescents by pediatricians and psychiatrists, and
the small number of professionals specializing in child psychiatry
in Brazil (45). Across the country, we have few public and pri-
vate services available to make appropriate diagnoses and afford
treatment. In addition, there is great concern in university and
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government sectors over the possible over-treatment of children
and adolescents with ADHD in our country. However, in fact, it
is estimated that only 16.2–19.9% of individuals affected by Brazil
received first-line treatment for the disorder in 2009–2010 (46).
In reality, the actual number in treatment is probably lower
still because these stimulants can also be used for other purposes,
though less frequently (46). Thus, a patient with ADHD can
remain undiagnosed and untreated for many years, and this may
result in increased persistence of symptoms and development of
comorbidities. However, these results seem to agree with previous
reports documenting that ADHD is a highly persistent disor-
der (13, 17, 19, 22, 25, 47, 48) and that patterns of persistence
and remission can be predicted over the long term into young
adult life.
The patients included at baseline had a diagnosis of ADHD
without comorbidities. Four years later, the comorbidity rate was
75%. This rate was higher than those found in other studies:
46.4% (49), 46.6% (35), and 50% (13). Such differences could per-
haps be explained by sample characteristics because in this study
the patients were selected from a center specialized in ADHD
treatment, a reference in the area, thus potentially composed of
patients with more severe forms of the illness andmore thus more
likely to seek treatment.
In this work, persistent ADHD was associated with significant
rates of ODD, CD, and affective problems compared with con-
trols. This result is consistent with previous studies showing that
comorbidities, particularly behavioral problems, are predictors
of lifelong ADHD persistence (7, 8, 22, 30, 31, 50). Although
the disruptive behavior disorders (ODD and CD) are consid-
ered phenomenologically different, comorbidity is very common.
Disruptive behavioral disorders (DBD) and ADHD are both
characterized by certain patterns of misbehavior among adoles-
cents. Studies have shown that the severity of CD symptoms is
associated with comorbid DBD and ADHD. Adolescents diag-
nosed with comorbid DBD and ADHD had an increased risk
for anxiety disorders, depressive disorders, and substance abuse
disorders. The comorbidity between DBD and ADHD should
be considered in clinical practice because it could indicate more
serious problematic behaviors than in the pure disorders alone
(51, 52).
Regarding ADHD’s comorbidity with mood disorder, recently
studies have reported depression in 14% of ADHD children vs. 1%
of those without ADHD (53). A review of comorbid depression in
community samples has reported that the rate of MDD in youths
with ADHD is 5.5 times higher than in youths without ADHD,
with rates ranging from 12 to 50% (54). Overlapping symptoms
between bipolar disorder (BD) andADHDmake differential diag-
nosis a complex clinical task (55). It is noteworthy that up to
20% of children diagnosed with ADHD meet the criteria for BD
and 50% of adolescents with BD meet the criteria for ADHD
(56, 57). The rate in this 4-year follow-up study differed from
others. Possibly the characteristics of our sample could explain the
higher rates of comorbidity with affective disorders (poverty, poor
access to treatment, low use of medication, and maybe chronic
frustration and disappointment of living with untreated or poorly
managed ADHD). ADHD’s comorbidity with mood disorders
(MDD, DD, and BD) emphasizes the need for early detection and
intervention to prevent, delay, or reduce its severity and associated
impairments associated over time.
In relation to schooling, more than half the experimental group
participants had been suspended or expelled in the latest data
collection year. Our results confirm previous work showing that
ADHD in childhood is associated with dropping out of school,
significantly higher rates of repeated grades, tutoring, placement
in special classes, reading disability, and fewer years of schooling
attained. Thus, ADHD may increase the risk of adverse edu-
cational outcomes related to these symptoms in childhood and
adolescence (10, 58, 59).
We observed that the number of children on medication for
ADHD was very small (seven patients). Five of the seven patients
were of the most favored social class and possibly had easier
access to medical services and medication purchase. Despite sub-
stantial evidence supporting the efficacy of stimulant medication
for children with (ADHD), adherence to stimulant treatment
is often suboptimal (60). Many children discontinue the use of
medication within the first year due to adverse effects or do
not realize the effectiveness of treatment (61). Furthermore, the
parent usually makes the healthcare decisions for children, and
only some adolescents could make their own decisions. Among
the factors that lead to lower adherence to treatment are the
following: belief that the symptoms are not a disorder; distrust
of the medical system; cost of medication; lack of providers in
the community; and lack of insurance coverage (60, 62, 63).
The data from this work confirm these findings and may be
related to difficulties in access to treatment, medication pur-
chase, and the lack of public policies in Brazil. Thus, there is
necessity to improve the management of side effects, setting
realistic treatment goals and constantly evaluating the success
of therapy.
There are limitations to this study. The first is the relatively
small sample size, occasioned by the strict inclusion criteria. A
second limitation is the gender distribution with few girls, making
it difficult to generalize the results. However, the predominance of
boys in the sample is consistent with previous studies and in the
general population. A third limitation is represented by the sample
loss in the control group in the 4-year follow-up.
Conclusion
Our results are relative to a population with potentially more
severe ADHD (because they searched for treatment) and may not
correspond with what happens with individuals with ADHDwho
do not seek treatment. The current analyses suggest that a small
number of children with ADHD attain complete remission and
the persistence of symptoms might be associated with more psy-
chiatric comorbidities. This can indicate that the comorbid disor-
der is also persistent, and should encourage clinicians to carefully
monitor comorbidities in children with ADHD and to be attentive
to the residual manifestations of the symptoms of this disease over
time. The results could suggest that a lack of effective pharmaco-
logical and psychosocial interventions and early diagnosis could
aggravate the core symptoms of ADHD, leading to persistence of
symptoms and the development of comorbidities, especially with
ODD/CD. However, small number of children and adolescents
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with ADHD were treated effectively throughout the course of
the disorder (64), and they tended to be so only for a short
time. Thus, clinicians and pediatricians should be encouraged
to carefully monitor children with ADHD and observe both
manifestations of residual symptoms over time and comorbid-
associated disorders. Furthermore, the improvement of the
diagnosis of ADHD; frequent monitoring of cases already
diagnosed; and the formulation of public health policies for
these children and adolescents could have a substantial impact
on the development of the disorder. In developing coun-
tries, such as Brazil, a better understanding of the long-term
outcomes of children and adolescents with ADHD could
help in the implementation of limited financial resources on
programs and projects targeted to patients with poor outcome
(cases of comorbidity, legal problems, abandonment school,
etc.), (65).
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